Edition:
India

Retrophin Inc (RTRX.OQ)

RTRX.OQ on NASDAQ Stock Exchange Global Market

28.50USD
18 Jun 2018
Change (% chg)

-- (--)
Prev Close
$28.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
146,569
52-wk High
$29.74
52-wk Low
$18.13

Select another date:

Wed, May 2 2018

BRIEF-Retrophin Q1 Loss Per Share $0.46

* Q1 EARNINGS PER SHARE VIEW $-0.45 -- THOMSON REUTERS I/B/E/S

BRIEF-Retrophin Initiates Pivotal Phase 3 Clinical Trial Of Sparsentan For The Treatment Of Focal Segmental Glomerulosclerosis

* RETROPHIN INITIATES PIVOTAL PHASE 3 CLINICAL TRIAL OF SPARSENTAN FOR THE TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS Source text for Eikon: Further company coverage:

BRIEF-Ligand Pharmaceuticals Says ‍Entered Amendment No. 5 To Sublicense Agreement With Retrophin

* LIGAND PHARMACEUTICALS SAYS ‍ON MARCH 20, CO ENTERED INTO AMENDMENT NO. 5 TO SUBLICENSE AGREEMENT, DATED FEB 16, 2012 WITH RETROPHIN, INC- SEC FILING​

BRIEF-Retrophin Inc Q4 Loss Per Share $0.45

* RETROPHIN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Retrophin Expects Total Net Product Sales Of Approximately $155 Million​ In 2018

* ‍FOR FISCAL YEAR 2017, COMPANY EXPECTS TOTAL NET PRODUCT SALES OF APPROXIMATELY $155 MILLION​

BRIEF-Retrophin And Censa Pharmaceuticals Enter Into Strategic Collaboration To Advance Cnsa-001

* RETROPHIN AND CENSA PHARMACEUTICALS ENTER INTO STRATEGIC COLLABORATION TO ADVANCE CNSA-001 FOR THE TREATMENT OF PHENYLKETONURIA (PKU)

BRIEF-Retrophin Enters Into Future Acquisition Right, Joint Development Agreement With Censa Pharma

* RETROPHIN SAYS ON DEC 16, CO ENTERED INTO FUTURE ACQUISITION RIGHT, JOINT DEVELOPMENT AGREEMENT WITH CENSA PHARMA - SEC FILING

Select another date: